Molecular Templates to Screen Targets for ImClone | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Templates, a Georgetown, Texas-based firm that has developed a targeted biologics platform, said that it has signed an agreement to screen potential drug targets for ImClone Systems, a wholly-owned subsidiary of Eli Lilly.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.